Form D · Pharmaceuticals
Jaguar Holding Co I
Wilmington, NC · CIK 0001552661
Offering snapshot reported Jun 21, 2012 · SEC filing
- Reported sold
- $1.25M Offering amount: $3.5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 7, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 21, 2012 | Initial | $1,250,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-180072
Source: Form D, filed Jun 21, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Karen Bechtel | Director |
| Peter J. Clare | Director |
| Daniel G. Darazsdi | Executive |
| Robert Essner | Director |
| B. Judd Hartman | Executive |
| Jeffrey Kindler | Director |
| Martin Madaus | Director |
| P. Hunter Philbrick | Director |
| Charles Rozwat | Director |
| William J. Sharbaugh | Executive |
| David Simmons | Director, Executive |
| Allen Thorpe | Director |
| Brian Tuttle | Executive |
| Stephen H. Wise | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
929 North Front Street
Wilmington, NC, 28401
Wilmington, NC, 28401